Table 2.
Characteristics of the chest wall recurrences (CWRs).
| Clinical Features N = 194 | Patients with No Axillary Surgery at CWR N = 181/(%) |
Patients with Sentinel Lymph Node Biopsy and/or Axillary Lymph Node Dissection at CWR N = 13/(%) |
p Value |
|---|---|---|---|
| Age (years) at recurrence | 0.486 | ||
| <50 | 59 (32.6%) | 6 (46.2%) | |
| ≥50 | 122 (67.4%) | 7 (53.8%) | |
| Pathological features of the recurrences | 0.072 | ||
| Invasive tumour size (mm) 1 | |||
| ≤20 | 72 (72.0) | 3 (37.5%) | |
| >20 to ≤50 | 25 (25.0) | 5 (62.5%) | |
| >50 | 3 (3.0) | 0 (0) | |
| Not available | 81 | 5 | |
| Tumour histology | 0.078 | ||
| Invasive ductal | 116 (80.0) | 8 (66.7) | |
| Invasive lobular | 12 (8.3) | 0 (0.0) | |
| Others | 17 (11.7) | 4 (33.3) | |
| Unknown | 36 | 1 | |
| Grade | 0.387 | ||
| I | 11 (10.2) | 0 (0) | |
| II | 56 (51.9) | 6 (75.0) | |
| III | 41 (38.0) | 2 (25.0) | |
| Not available | 73 | 5 | |
| Oestrogen receptor (ER) | 1.000 | ||
| Positive | 138 (83.1) | 11 (84.6) | |
| Negative | 28 (16.9) | 2 (15.4) | |
| Not available | 15 | 0 | |
| Progesterone receptor (PR) | 0.461 | ||
| Positive | 95 (59.7) | 9 (75.0) | |
| Negative | 64 (40.3) | 3 (25.0) | |
| Not available | 22 | 1 | |
| Human epidermal growth factor receptor 2 (HER2) | 0.923 | ||
| Positive | 30 (21.1) | 3 (27.3) | |
| Negative | 112 (78.9) | 8 (72.7) | |
| Not available | 39 | 2 | |
| Pathological nodal involvement 2 | - | ||
| Yes | - | 1 (8.3) | |
| No | - | 11 (91.7) | |
| Unknown | 1 | ||
| Chemotherapy | 0.237 | ||
| Yes | 43 (32.1) | 6 (54.5) | |
| No | 91 (67.9) | 5 (45.5) | |
| Unknown | 47 | 2 | |
| Radiotherapy | 0.291 | ||
| Yes | 120 (66.3) | 11 (84.6) | |
| No | 61 (33.7) | 2 (15.4) | |
| Hormonal therapy | 0.841 | ||
| Yes | 132 (78.1) | 11 (84.6) | |
| No | 37 (21.9) | 2 (15.4) | |
| Not available/not applicable | 12 | 0 | |
| Targeted HER2 therapy | 1.000 | ||
| Yes | 13 (50.0) | 2 (66.7) | |
| No | 13 (50.0) | 1 (33.3) | |
| Unknown/not applicable | 155 | 10 | |
| Ipsilateral axillary recurrence as subsequent recurrence | 0.768 | ||
| Yes | 11 (6.1) | 0 (0.0) | |
| No | 170 (93.9) | 13 (100.0) | |
| Second recurrence | 0.061 | ||
| No | 113 (62.4) | 12 (92.3) | |
| Yes | 68 (37.6) | 1 (7.7) |
1 Based on the largest invasive tumour size if multiple lesions present. 2 Based on the patients who underwent axillary surgery.